Literature DB >> 32433283

Taking a Second Look at Neoadjuvant Endocrine Therapy for the Treatment of Early Stage Estrogen Receptor Positive Breast Cancer During the COVID-19 Outbreak.

Carlie K Thompson1, Minna K Lee, Jennifer L Baker, Deanna J Attai, Maggie L DiNome.   

Abstract

Year:  2020        PMID： 32433283      PMCID： PMC7268854          DOI： 10.1097/SLA.0000000000004027

Source DB:  PubMed          Journal:  Ann Surg        ISSN： 0003-4932            Impact factor:   12.969


× No keyword cloud information.
  15 in total

1.  Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.

Authors:  Davide Mauri; Nicholas Pavlidis; John P A Ioannidis
Journal:  J Natl Cancer Inst       Date:  2005-02-02       Impact factor: 13.506

2.  Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast Cancer.

Authors:  Sara A Hurvitz; Miguel Martin; Michael F Press; David Chan; María Fernandez-Abad; Edgar Petru; Regan Rostorfer; Valentina Guarneri; Chiun-Sheng Huang; Susana Barriga; Sameera Wijayawardana; Manisha Brahmachary; Philip J Ebert; Anwar Hossain; Jiangang Liu; Adam Abel; Amit Aggarwal; Valerie M Jansen; Dennis J Slamon
Journal:  Clin Cancer Res       Date:  2019-10-15       Impact factor: 12.531

3.  Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.

Authors:  Mitch Dowsett; Steve R Ebbs; J Michael Dixon; Anthony Skene; Clive Griffith; Irene Boeddinghaus; Janine Salter; Simone Detre; Margaret Hills; Susan Ashley; Stephen Francis; Geraldine Walsh; Ian E Smith
Journal:  J Clin Oncol       Date:  2005-03-14       Impact factor: 44.544

4.  Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.

Authors:  Matthew J Ellis; Vera J Suman; Jeremy Hoog; Li Lin; Jacqueline Snider; Aleix Prat; Joel S Parker; Jingqin Luo; Katherine DeSchryver; D Craig Allred; Laura J Esserman; Gary W Unzeitig; Julie Margenthaler; Gildy V Babiera; P Kelly Marcom; Joseph M Guenther; Mark A Watson; Marilyn Leitch; Kelly Hunt; John A Olson
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

Review 5.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

Authors:  Patricia Cortazar; Lijun Zhang; Michael Untch; Keyur Mehta; Joseph P Costantino; Norman Wolmark; Hervé Bonnefoi; David Cameron; Luca Gianni; Pinuccia Valagussa; Sandra M Swain; Tatiana Prowell; Sibylle Loibl; D Lawrence Wickerham; Jan Bogaerts; Jose Baselga; Charles Perou; Gideon Blumenthal; Jens Blohmer; Eleftherios P Mamounas; Jonas Bergh; Vladimir Semiglazov; Robert Justice; Holger Eidtmann; Soonmyung Paik; Martine Piccart; Rajeshwari Sridhara; Peter A Fasching; Leen Slaets; Shenghui Tang; Bernd Gerber; Charles E Geyer; Richard Pazdur; Nina Ditsch; Priya Rastogi; Wolfgang Eiermann; Gunter von Minckwitz
Journal:  Lancet       Date:  2014-02-14       Impact factor: 79.321

6.  Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.

Authors:  Norikazu Masuda; Soo-Jung Lee; Shoichiro Ohtani; Young-Hyuck Im; Eun-Sook Lee; Isao Yokota; Katsumasa Kuroi; Seock-Ah Im; Byeong-Woo Park; Sung-Bae Kim; Yasuhiro Yanagita; Shinji Ohno; Shintaro Takao; Kenjiro Aogi; Hiroji Iwata; Joon Jeong; Aeree Kim; Kyong-Hwa Park; Hironobu Sasano; Yasuo Ohashi; Masakazu Toi
Journal:  N Engl J Med       Date:  2017-06-01       Impact factor: 91.245

7.  Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

Authors:  Gunter von Minckwitz; Chiun-Sheng Huang; Max S Mano; Sibylle Loibl; Eleftherios P Mamounas; Michael Untch; Norman Wolmark; Priya Rastogi; Andreas Schneeweiss; Andres Redondo; Hans H Fischer; William Jacot; Alison K Conlin; Claudia Arce-Salinas; Irene L Wapnir; Christian Jackisch; Michael P DiGiovanna; Peter A Fasching; John P Crown; Pia Wülfing; Zhimin Shao; Elena Rota Caremoli; Haiyan Wu; Lisa H Lam; David Tesarowski; Melanie Smitt; Hannah Douthwaite; Stina M Singel; Charles E Geyer
Journal:  N Engl J Med       Date:  2018-12-05       Impact factor: 176.079

8.  Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).

Authors:  Matthew J Ellis; Vera J Suman; Jeremy Hoog; Rodrigo Goncalves; Souzan Sanati; Chad J Creighton; Katherine DeSchryver; Erika Crouch; Amy Brink; Mark Watson; Jingqin Luo; Yu Tao; Michael Barnes; Mitchell Dowsett; G Thomas Budd; Eric Winer; Paula Silverman; Laura Esserman; Lisa Carey; Cynthia X Ma; Gary Unzeitig; Timothy Pluard; Pat Whitworth; Gildy Babiera; J Michael Guenther; Zoneddy Dayao; David Ota; Marilyn Leitch; John A Olson; D Craig Allred; Kelly Hunt
Journal:  J Clin Oncol       Date:  2017-01-03       Impact factor: 44.544

9.  Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.

Authors:  Matthew J Ellis; Yu Tao; Jingqin Luo; Roger A'Hern; Dean B Evans; Ajay S Bhatnagar; Hilary A Chaudri Ross; Alexander von Kameke; William R Miller; Ian Smith; Wolfgang Eiermann; Mitch Dowsett
Journal:  J Natl Cancer Inst       Date:  2008-09-23       Impact factor: 13.506

Review 10.  Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.

Authors:  Sarah R Hosford; Todd W Miller
Journal:  Pharmgenomics Pers Med       Date:  2014-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.